Merck made a nonbinding offer of over $3 billion for MoonLake, whose lead drug is in Phase 3 trials for arthritis and skin disorders. Investor pressure is rising on Merck as Keytruda nears patent ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory ...

(Reuters) -Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.

Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline.

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in ...

Best of luck, everyone. … Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline, The Financial Times reports.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

June 2 (Reuters) - Merck (MRK.N), opens new tab has held talks to buy Swiss biotech MoonLake Immunotherapeutics (MLTX.O), opens new tab for more than $3 billion, the Financial Times reported on ...